Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX
Kiora Pharmaceuticals — Eyegate Pharmaceuticals — Investor Presentation (September 2019)
25 slides from Kiora Pharmaceuticals's investor presentation, Sep 9, 2019
Slide 1: Corporate Presentation
NASDAQ: EYEG Corporate Presentation
Slide 2: Forward-looking statements
Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company’s OBG and EGP - 437 product candidates , for the timing and outcome of the Company’s clinical trial
Slide 3: EyeGate Pharma: Company Highlights
3 EyeGate Pharma: Company Highlights Nasdaq: EYEG » Lead product is the Ocular Bandage Gel (OBG), a unique, first - in - class eye drop formulation » Hyaluronic acid, or HA, is a natural substance in the body that promotes wound healing and provides hydration and lubrication . Modified HA is the mai
Slide 4: EyeGate Pharma: Financial Highlights
4 EyeGate Pharma: Financial Highlights » To comply with NASDAQ listing requirement, completed 1 - for - 15 reverse split on Aug 30, 2019 » Cash position at Q2 2019 was ~$4.5Mn and no debt Outstanding as of 8/30/19* Common Stock Outstanding 3,045,026 46% Preferred Stock Outstanding 852,500 13% Warran
Slide 5: Strong & Experienced Leadership Team
Strong & Experienced Leadership Team Stephen From President & Chief Executive Officer Sarah Romano Chief Financial Officer Michael Manzo Vice President of Engineering Lisa Brandano Vice President of Clinical Operations Barbara Wirostko , M.D. Medical Advisor (former Chief Medical Officer) Brenda Man
Slide 6: Ocular Bandage Gel (OBG) Eye Drop
Ocular Bandage Gel (OBG) Eye Drop
Slide 7: Ocular Bandage Gel (OBG) Highlights
7 Ocular Bandage Gel (OBG) Highlights » Highly purified, crosslinked version of HA in a buffer with no other ingredients » Will be the only prescription HA eye drop in the U.S. » The only covalently crosslinked HA eye drop in the world ▪ This modification of HA prevents degradation providing device
Slide 8: What is Hyaluronic Acid (HA)?
8 What is Hyaluronic Acid (HA)? HA is a Naturally Occurring Molecule in our Body with Several Beneficial Properties Hyaluronic Acid » HA is a material with a high viscosity (thickness) » Promotes wound healing by providing a mechanical barrier against blinking and external forces » Provides hydratio
Slide 9: Modified HA is Main Ingredient in OBG
Hyaluronic Acid Hyaluronic Acid Hyaluronic Acid 9 Crosslink Modified HA is Main Ingredient in OBG HA is modified and covalently crosslinked, which stabilizes the HA molecule providing the following characteristics: » Resistance to degradation: regular HA may cause inflammation when it degrades » Pro
Slide 10: OBG: Efficacy Demonstrated in Various Studies
10 OBG: Efficacy Demonstrated in Various Studies A B Molly: 12 year old cat with a non - healing corneal defect A. Non - healing at 42 days B. Ulcer healing after 12 days of using 0.75% CMHA - S Animal Studies » Post traumatic corneal stromal ulcers (real world dogs and cats) » Dry eye (veterinary d
Slide 11: OBG: Timeline to Launch
OBG: Timeline to Launch 11 Treating ocular surface pathologies and associated corneal injuries » The initial de novo review for OBG could take up to 9 months because it includes the review of both clinical and non - clinical items such as manufacturing and preclinical » The review period for the 2 n
Slide 12: Large Opportunity & Addressable Market
Large Opportunity & Addressable Market 12 Wounds: Surgery • Refractive surgeries (PRK) • LASIK • Collagen cross - linking Epitheliopathies: Dry Eye • Episodic / mild • Moderate • Severe Epitheliopathies: non - Dry Eye • Pre - Cataract Surgery • Contact lens wear • Ocular irritants • Glaucoma medicat
Slide 13: Clinical and Commercial Strategy
13 Clinical and Commercial Strategy » OBG heals the epithelial cells covering the cornea; there are many different types and sizes of epithelial defects from surgically induced to non - healing ulcers to micro - abrasions » Primary Objective: approval for treating all epithelial defects without doin
Slide 14: Wound Healing Studies
Wound Healing Studies
Slide 15: Demonstrating Wound Healing in PRK Patients
15 Demonstrating Wound Healing in PRK Patients » PRK is a surgical correction of refractive errors for patients who are not suitable candidates for LASIK due to: ▪ Inadequate corneal thickness ▪ Larger pupil size ▪ History of keratoconjunctivitis sicca (KCS) ▪ Anterior basement membrane disease » PR
Slide 16: EyeGate's Wound Healing Clinical Studies
EyeGate’s Wound Healing Clinical Studies Objective is to demonstrate acceleration of the healing process 15 Design for both of the pilot studies: • Treatment Group 1: OBG 4x/day (QID) for 14 days • Treatment Group 2: Study 1 (OBG combined with BCL), Study 2 (OBG 8x/day for 3 days followed by QID for
Slide 17: PRK: Positive Clinical Trial Results
PRK: Positive Clinical Trial Results 17 Acceleration of Re - epithelialization/Healing of a Large Wound Demonstrated Study 1 N Day 3 Day 4 Day 5 Treatment Group 1: OBG QID 12 10 (83.3%) 12 (100.0%) 12 (100.0%) Control Group: BCL + Artificial Tears 13 7 (53.8%) 13 (100.0%) 12 * (92.3%) Study 2 N Day
Slide 18: Pivotal Study Design (Ongoing)
Pivotal Study Design (Ongoing) Objective is to demonstrate acceleration of the healing process 17 » Two - arm, controlled pivotal study masked via reading center ▪ OBG (eye drop) vs. standard - of - care (bandage contact lens) ▪ Endpoint: percentage of eyes in each group with fully closed wound at D
Slide 19: PE Study
PE Study
Slide 20: About Punctate Epitheliopathies (PE)
20 About Punctate Epitheliopathies (PE) » Punctates are a sign of epithelial compromise and are characterized by a breakdown or damage of the epithelium of the cornea and therefore stain positively with fluorescein » Patients may present with non - specific symptoms such as tearing, foreign body sen
Slide 21: EyeGate's Punctate Epitheliopathies (PE) Study
EyeGate’s Punctate Epitheliopathies (PE) Study Objective is to reduce corneal staining and improve the accompanying symptoms 20 Pilot Study Design ▪ 30 subjects: 6 week study (2 week wash - out followed by 4 weeks of treatment) • 2 week wash - out period: all 30 patients stop taking prescription eye
Slide 22: PE Study Demonstrates Improvement in Symptoms
21 ▪ Symptomology data using SPEED TM questionnaire showed strong p - values at all follow - up days • OBG patients saw a decrease of 30% from baseline in reported symptoms • 73% of patients in the OBG group reported an improvement of symptoms while 53% of patients in the control group reported a wo
Slide 23: Staining Results of Central Cornea Supports Improved Symptoms Outcome
Staining Results of Central Cornea Supports Improved Symptoms Outcome 23 Central Cornea 1 Quickly Improves and Continues to Perform 1) Central Cornea important for visual field 2) Combined Data = Study eye + non - study eye ▪ This data supports and correlates with symptomology due to high concentrat
Slide 24: 2nd Pilot Study Design (Ongoing)
Objective is to evaluate several performance endpoints for use in pivotal study 23 » Two - arm, controlled study ▪ OBG vs. artificial tears ▪ Patient is their own control: both eyes must qualify where one eye is randomized to OBG and the other eye to artificial tears ▪ Randomizing up to 20 patients
Slide 25: Thank You / Contact Us
Thank You NASDAQ: EYEG Contact Us Joseph Green Edison Advisors Investor Relations Tel: (646) 653 - 7030 E - mail: jgreen@edisongroup.com
Eyegate Pharmaceuticals — Investor Presentation (September 2019) on 6ix